jRCT2080221614未知3 期
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)
试验速览
- 阶段
- 3 期
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Randomized, Double-blind, Multicenter
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.
排除标准
- •Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate).
- •Current drug-induced psoriasis.
- •Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.
结局指标
主要结局
-
PASI 75
次要结局
未报告次要终点
研究者
相似试验
未知
3 期
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)psoriasisJPRN-jRCT2080221614ovartis Pharma K.K.
未知
3 期
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)psoriasisJPRN-jRCT2080221490ovartis Pharma K.K.
已完成
3 期
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial SpondyloarthritisjRCT2080223230Novartis Pharma K.K.24
进行中（未招募）
1 期
An extension study of subcutaneous secukinumab in patients with Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)Enthesitis-Related Arthritis and Juvenile Psoriatic ArthritisMedDRA version: 20.0Level: LLTClassification code 10072745Term: Enthesitis related arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: PTClassification code 10076674Term: Juvenile psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2018-002521-30-ITOVARTIS PHARMA AG63
进行中（未招募）
1 期
An extension study of subcutaneous secukinumab in patients with Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)EUCTR2018-002521-30-ESovartis Farmacéutica, S.A.63